John M. Ketcham
0000-0001-5011-9593
Publication & Citation Trends
Most Cited Works
Publications
56 total
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading PDF
Cited by 27
OpenAlex
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein PDF
Cited by 18
OpenAlex
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i> -Deleted Cancers PDF
Cited by 140
OpenAlex
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction PDF
Cited by 89
OpenAlex
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors PDF
Cited by 15
OpenAlex
Fragment optimization and elaboration strategies – the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits PDF
Cited by 12
OpenAlex
Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors PDF
Cited by 26
OpenAlex
Discovery of a Potent and Selective CCR4 Antagonist That Inhibits T<sub>reg</sub> Trafficking into the Tumor Microenvironment PDF
Cited by 27
OpenAlex
Research Topics
ATP Synthase and ATPases Research
(16)
Biochemical and Molecular Research
(16)
Cytokine Signaling Pathways and Interactions
(14)
Catalytic C–H Functionalization Methods
(8)
Catalytic Alkyne Reactions
(7)
Frequent Co-Authors
Affiliations
University of Florida
Rapt Therapeutics (United States)
Regenxbio (United States)
Mirati Therapeutics (United States)
APT Therapeutics (United States)